Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty
NCT ID: NCT00831714
Last Updated: 2017-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
19076 participants
OBSERVATIONAL
2009-02-28
2013-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)
NCT01523418
Xarelto Regulatory Post-Marketing Surveillance
NCT01029743
Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty
NCT05449327
Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)
NCT02558465
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
NCT02504216
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Rivaroxaban (Xarelto, BAY59-7939)
Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made
Group 2
Standard care treatment for VTE prophylaxis
Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rivaroxaban (Xarelto, BAY59-7939)
Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made
Standard care treatment for VTE prophylaxis
Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen Research & Development, LLC
INDUSTRY
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Many Locations, , Australia
Many Locations, , Austria
Many Locations, , Belgium
Many Locations, , Bosnia and Herzegovina
Many Locations, , Brazil
Many Locations, , Canada
Many Locations, , Chile
Many Locations, , China
Many Locations, , Colombia
Many Locations, , Cyprus
Many Locations, , Czechia
Many Locations, , Denmark
Many Locations, , Estonia
Many Locations, , Finland
Many Locations, , France
Many Locations, , Germany
Many Locations, , Greece
Many Locations, , Hong Kong
Many Locations, , Hungary
Many Locations, , India
Many Locations, , Italy
Many Locations, , Latvia
Many Locations, , Lebanon
Many Locations, , Lithuania
Many Locations, , Mexico
Many Locations, , Netherlands
Many Locations, , North Macedonia
Many Locations, , Norway
Many Locations, , Philippines
Many Locations, , Portugal
Many Locations, , Serbia
Many Locations, , Singapore
Many Locations, , Slovakia
Many Locations, , South Africa
Many Locations, , South Korea
Many Locations, , Spain
Many Locations, , Sweden
Many Locations, , Switzerland
Many Locations, , United Arab Emirates
Many Locations, , United Kingdom
Many Locations, , Venezuela
Many Locations, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Turpie AG, Haas S, Kreutz R, Mantovani LG, Pattanayak CW, Holberg G, Jamal W, Schmidt A, van Eickels M, Lassen MR. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thromb Haemost. 2014 Jan;111(1):94-102. doi: 10.1160/TH13-08-0666. Epub 2013 Oct 24.
Turpie AG, Schmidt AC, Kreutz R, Lassen MR, Jamal W, Mantovani L, Haas S. Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. Vasc Health Risk Manag. 2012;8:363-70. doi: 10.2147/VHRM.S30064. Epub 2012 Jun 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XA0801
Identifier Type: OTHER
Identifier Source: secondary_id
13802
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.